2022 Fiscal Year Final Research Report
Novel immunotherapy targeting to Neo-antigen specific T cell for lung cancer
| Project/Area Number |
19K09310
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55040:Respiratory surgery-related
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | 肺癌 / 免疫療法 / T細胞療法 |
|---|
| Outline of Final Research Achievements |
The aim of this study was to clarify the rationale for a novel cell-based cancer immunotherapy targeting specific T cells in the tumor microenvironment. We first analyzed the tumor microenvironment in detail and found that the presence of tertiary lymphoid-like structures (TLS) is associated with the prognosis of lung cancer patients and the efficacy of immunotherapy. On the other hand, we confirmed the frequency and behavior of CD8 T cells with specific T cell receptors at the tumor site, and confirmed the expansion of tumor-specific T cells to the periphery. These results provide important basic data for the practical application of tumor-specific T-cell therapy.
|
| Free Research Field |
呼吸器外科
|
| Academic Significance and Societal Importance of the Research Achievements |
各種癌に対する免疫チェックポイント阻害薬（ICI）を用いた治療が開発され，一部の症例では劇的な効果を発揮する．しかしその効果は限定的であり効果予測因子の抽出とさらなる効果の向上が求められている．本研究によって，腫瘍微小環境におけるTLSの存在が肺癌患者の予後のみならずICI療法の効果予測因子になることを明らかにした点で意義が大きい．また微小環境のみならず末梢血における変化も確認しており，今後の応用が期待される．また，特定のTCRクローンの挙動を解明することで，今後新たな細胞療法の可能性に貢献する結果を得ることができた．
|
